Abstract
Recent guidelines have promoted a lifecycle approach to analytical methods. Mimicking a similar paradigm in vaccine product development, this draws attention to a science and risk-based pathway and tools which help ensure successful analytical method development and lifecycle management. However, adoption and implementation of this approach faces serious hurdles, some cultural and others regulatory. This article will describe some key elements and give notification of challenges which must be considered as the vaccines industry and regulators embark on implementing a lifecycle approach to vaccine analytical methods. 
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
